FME Stock Overview
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Fresenius Medical Care AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.45 |
| 52 Week High | €0 |
| 52 Week Low | €0 |
| Beta | 0.84 |
| 1 Month Change | 20.56% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -40.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| FME | CH Healthcare | CH Market | |
|---|---|---|---|
| 7D | 20.6% | -1.1% | -0.5% |
| 1Y | n/a | 4.0% | 2.8% |
Return vs Industry: Insufficient data to determine how FME performed against the Swiss Healthcare industry.
Return vs Market: Insufficient data to determine how FME performed against the Swiss Market.
Price Volatility
| FME volatility | |
|---|---|
| FME Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 4.2% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 7.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: FME's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: Insufficient data to determine FME's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 113,079 | Helen Giza | www.freseniusmedicalcare.com |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
Fresenius Medical Care AG Fundamentals Summary
| FME fundamental statistics | |
|---|---|
| Market cap | CHF 12.01b |
| Earnings (TTM) | CHF 614.19m |
| Revenue (TTM) | CHF 17.93b |
19.5x
P/E Ratio0.7x
P/S RatioIs FME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FME income statement (TTM) | |
|---|---|
| Revenue | €19.24b |
| Cost of Revenue | €14.40b |
| Gross Profit | €4.84b |
| Other Expenses | €4.18b |
| Earnings | €658.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.25 |
| Gross Margin | 25.14% |
| Net Profit Margin | 3.43% |
| Debt/Equity Ratio | 49.4% |
How did FME perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield53%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 22:13 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresenius Medical Care AG is covered by 59 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Brian Williams | Avondale Partners |
| Olav Zilian | Baader Helvea Equity Research |